The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
H | Systemic hormonal preparations, excl. Sex hormones and insulins | |
2
|
H01 | Pituitary and hypothalamic hormones and analogues | |
3
|
H01C | Hypothalamic hormones | |
4
|
H01CC | Anti-gonadotropin-releasing hormones | |
5
|
H01CC01 | Ganirelix |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Code | Route | Amount | Notes |
|---|---|---|---|
| PAREN | Parenteral | 0.25 mg |
| Active Ingredient |
|---|
|
Ganirelix is a GnRH antagonist, which modulates the hypothalamic-pituitary-gonadal axis by competitive binding to the GnRH receptors in the pituitary gland. As a result a rapid, profound, reversible suppression of endogenous gonadotrophins occurs, without initial stimulation as induced by GnRH agonists. |
| Document | Type | Information Source | |
|---|---|---|---|
| FYREMADEL Solution for injection in pre-filled syringe | MPI, EU: SmPC | Medicines & Healthcare Products Regulatory Agency (GB) | |
| ORGALUTRAN Solution for injection | MPI, EU: SmPC | European Medicines Agency (EU) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.